Market Research Life Sciences Market Research Pharmaceuticals Market Research Therapeutic Area Market Research Orthopedics Market Research

Osteoarthritis Epidemiology Analysis and Forecast, 2021-2031

Best Price Guarantee Length Publisher Published Date SKU
from $3,995 52 Pages GlobalData June, 2022 GBDT17335444
Best Price Guarantee
Price from $3,995
Length 52 Pages
Publisher GlobalData
Published Date June, 2022
SKU GBDT17335444

Osteoarthritis Epidemiology Analysis and Forecast, 2021-2031

Summary

Osteoarthritis (OA) is a slowly progressive joint disease that is typically seen in middle-aged to elderly people. It is characterized by the breakdown of the cartilage, bony changes of the joints, deterioration of tendons and ligaments, and various degrees of inflammation of the joint lining. OA can occur in more than one region of the body simultaneously and most commonly affects joints in the knee, hip, hand, and spine.

In the 7MM, symptomatic diagnosed prevalent cases of hand OA are expected to increase from 75,194,395 cases in 2021 to 82,739,266 cases in 2031, at an annual growth rate (AGR) of 1.00%. In 2031, the US will have the highest number of symptomatic diagnosed prevalent cases of hand OA in the 7MM, with 36,738,291 cases, whereas the UK will have the fewest symptomatic diagnosed prevalent cases of hand OA with 2,819,264 cases.

In the 7MM, symptomatic diagnosed prevalent cases of knee OA are expected to increase from 20,257,631 cases in 2021 to 22,626,173 cases in 2031, at an AGR of 1.17%. In 2031, the US will have the highest number of diagnosed symptomatic prevalent cases of knee OA in the 7MM, with 10,090,439 cases, whereas France will have the fewest symptomatic diagnosed prevalent cases of knee OA with 728,487 cases.

In the 7MM, symptomatic diagnosed prevalent cases of hip OA are expected to increase from 3,493,407 cases in 2021 to 3,975,929 cases in 2031, at an AGR of 1.38%. In 2031, the US will have the highest number of symptomatic diagnosed prevalent cases of hip OA in the 7MM, with 2,068,615 cases, whereas Germany will have the fewest symptomatic diagnosed prevalent cases of hip OA with 92,268 cases.

Scope

  • This report provides an overview of the risk factors, comorbidities, and the global and historical trends for osteoarthritis (OA) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report provides a 10-year epidemiological forecast for the total prevalent cases (radiographic), total prevalent cases (symptomatic), and diagnosed prevalent cases (symptomatic) of hand OA, knee OA, and hip OA segmented by age (18 years and older) and sex in these markets.
  • The diagnosed prevalent cases (symptomatic) of hand OA, knee OA, and hip OA are further segmented by severity using Kellgren-Lawrence (KL) grading into mild (KL = 2), and moderate to severe (KL = 3 to 4). The model accompanying this report also provides the total prevalent cases (radiographic), total prevalent cases (symptomatic), and diagnosed prevalent cases (symptomatic) of hand OA, knee OA, and hip OA and the listed segments.
  • The osteoarthritis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to Buy

The osteoarthritis epidemiology series will allow you to -
  • Develop business strategies by understanding the trends shaping and driving the global osteoarthritis market.
  • Quantify patient populations in the global osteoarthritis market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups that present the best opportunities for osteoarthritis therapeutics in each of the markets covered.
  • Enable to understand the magnitude of hand, knee, and hip osteoarthritis and the severity.


1 Osteoarthritis: Executive Summary
1.1 Catalyst
1.2 Related Reports
1.3 Upcoming Reports
2 Epidemiology
2.1 Disease Background
2.2 Risk Factors and Comorbidities
2.3 Global and Historical Trends
2.4 7MM Forecast Methodology
2.4.1 Sources
2.4.2 Forecast Assumptions and Methods
2.4.3 Forecast Assumptions and Methods: Total Prevalent Cases (Radiographic)
2.4.4 Forecast Assumptions and Methods: Total Prevalent Cases (Symptomatic)
2.4.5 Forecast Assumptions and Methods: Diagnosed Prevalent Cases (Symptomatic)
2.4.6 Forecast Assumptions and Methods: Diagnosed Prevalent Cases (Symptomatic) by Severity
2.5 Epidemiological Forecast for OA (2021-31)
2.5.1 Total Prevalent Cases (Radiographic) of Hand OA
2.5.2 Total Prevalent Cases (Symptomatic) of Hand OA
2.5.3 Diagnosed Prevalent Cases (Symptomatic) of Hand OA
2.5.4 Age-Specific Diagnosed Prevalent Cases (Symptomatic) of Hand OA
2.5.5 Sex-Specific Diagnosed Prevalent Cases (Symptomatic) of Hand OA
2.5.6 Diagnosed Prevalent Cases (Symptomatic) of Hand OA by Severity
2.5.7 Total Prevalent Cases (Radiographic) of Knee OA
2.5.8 Total Prevalent Cases (Symptomatic) of Knee OA
2.5.9 Diagnosed Prevalent Cases (Symptomatic) of Knee OA
2.5.10 Age-Specific Diagnosed Prevalent Cases (Symptomatic) of Knee OA
2.5.11 Sex-Specific Diagnosed Prevalent Cases (Symptomatic) of Knee OA
2.5.12 Diagnosed Prevalent Cases (Symptomatic) of Knee OA by Severity
2.5.13 Total Prevalent Cases (Radiographic) of Hip OA
2.5.14 Total Prevalent Cases (Symptomatic) of Hip OA
2.5.15 Diagnosed Prevalent Cases (Symptomatic) of Hip OA
2.5.16 Age-Specific Diagnosed Prevalent Cases (Symptomatic) of Hip OA
2.5.17 Sex-Specific Diagnosed Prevalent Cases (Symptomatic) of Hip OA
2.5.18 Diagnosed Prevalent Cases (Symptomatic) of Hip OA by Severity
2.6 Discussion
2.6.1 Epidemiological Forecast Insight
2.6.2 COVID-19 Impact
2.6.3 Limitations of the Analysis
2.6.4 Strengths of the Analysis
3 Appendix
3.1 Bibliography
3.2 About the Authors
3.2.1 Epidemiologist
3.2.2 Reviewers
3.2.3 Global Director of Therapy Analysis and Epidemiology
3.2.4 Global Head and EVP of Healthcare Operations and Strategy
Contact Us
List of Tables
Table 1: Summary of Updated Data Types
Table 2: Risk Factors and Comorbid Conditions Associated with OA
Table 3: Severity Scoring System for Classifying the Hand, Knee, and Hip OA Using the KL Grading Scale
List of Figures
Figure 1: 7MM, Diagnosed Prevalent Cases (Symptomatic) of Hand OA, Both Sexes, N, Ages ≥18 Years, 2021 and 2031
Figure 2: 7MM, Diagnosed Prevalent Cases (Symptomatic) of Knee OA, Both Sexes, N, Ages ≥18 Years, 2021 and 2031
Figure 3: 7MM, Diagnosed Prevalent Cases (Symptomatic) of Hip OA, Both Sexes, N, Ages ≥18 Years, 2021 and 2031
Figure 4: 7MM, Diagnosed Prevalence (Symptomatic) (%), Hand OA, Both Sexes, Ages ≥18 Years, 2021
Figure 5: 7MM, Diagnosed Prevalence (Symptomatic) (%), Knee OA, Both Sexes, Ages ≥18 Years, 2021
Figure 6: 7MM, Diagnosed Prevalence (Symptomatic) (%), Hip OA, Both Sexes, Ages ≥18 Years, 2021
Figure 7: 7MM, Sources Used to Forecast the Total Prevalent Cases (Radiographic), Hand OA
Figure 8: 7MM, Sources Used to Forecast the Total Prevalent Cases (Radiographic), Knee OA
Figure 9: 7MM, Sources Used to Forecast the Total Prevalent Cases (Radiographic), Hip OA
Figure 10: 7MM, Sources Used to Forecast the Total Prevalent Cases (Symptomatic), Hand OA
Figure 11: 7MM, Sources Used and Not Used to Forecast the Total Prevalent Cases (Symptomatic), Knee OA
Figure 12: 7MM, Sources Used and Not Used to Forecast the Total Prevalent Cases (Symptomatic), Hip OA
Figure 13: 7MM, Total Prevalent Cases (Radiographic) of Hand OA, Both Sexes, Ages ≥18 Years, N, 2021
Figure 14: 7MM, Total Prevalent Cases (Symptomatic) of Hand OA, Both Sexes, Ages ≥18 Years, N, 2021
Figure 15: 7MM, Diagnosed Prevalent Cases (Symptomatic) of Hand OA, Both Sexes, Ages ≥18 Years, N, 2021
Figure 16: 7MM, Age-Specific Diagnosed Prevalent Cases (Symptomatic) of Hand OA, Both Sexes, Ages ≥18 Years, N, 2021
Figure 17: 7MM, Sex-Specific Diagnosed Prevalent Cases (Symptomatic) of Hand OA, Both Sexes, Ages ≥18 Years, N, 2021
Figure 18: 7MM, Diagnosed Prevalent Cases (Symptomatic) of Hand OA by Severity, Both Sexes, Ages ≥18 Years, N, 2021
Figure 19: 7MM, Total Prevalent Cases (Radiographic) of Knee OA, Both Sexes, Ages ≥18 Years, N, 2021
Figure 20: 7MM, Total Prevalent Cases (Symptomatic) of Knee OA, Both Sexes, Ages ≥18 Years, N, 2021
Figure 21: 7MM, Diagnosed Prevalent Cases (Symptomatic) of Knee OA, Both Sexes, Ages ≥18 Years, N, 2021
Figure 22: 7MM, Age-Specific Diagnosed Prevalent Cases (Symptomatic) of Knee OA, Both Sexes, Ages ≥18 Years, N, 2021
Figure 23: 7MM, Sex-Specific Diagnosed Prevalent Cases (Symptomatic) of Knee OA, Both Sexes, Ages ≥18 Years, N, 2021
Figure 24: 7MM, Diagnosed Prevalent Cases (Symptomatic) of Knee OA by Severity, Both Sexes, Ages ≥18 Years, N, 2021
Figure 25: 7MM, Total Prevalent Cases (Radiographic) of Hip OA, Both Sexes, Ages ≥18 Years, N, 2021
Figure 26: 7MM, Total Prevalent Cases (Symptomatic) of Hip OA, Both Sexes, Ages ≥18 Years, N, 2021
Figure 27: 7MM, Diagnosed Prevalent Cases (Symptomatic) of Hip OA, Both Sexes, Ages ≥18 Years, N, 2021
Figure 28: 7MM, Age-Specific Diagnosed Prevalent Cases (Symptomatic) of Hip OA, Both Sexes, Ages ≥18 Years, N, 2021
Figure 29: 7MM, Sex-Specific Diagnosed Prevalent Cases (Symptomatic) of Hip OA, Both Sexes, Ages ≥18 Years, N, 2021
Figure 30: 7MM, Diagnosed Prevalent Cases (Symptomatic) of Hip OA by Severity, Both Sexes, Ages ≥18 Years, N, 2021

$3,995
$7,990
$11,985

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings